Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808738 | 0.76 | HTT (0.33) | — | |
| SCHEMBL21293726 | 0.73 | KCNH2 (0.32) | — | |
| SCHEMBL21166 | 0.71 | — | — | |
| SCHEMBL6041393 | 0.70 | NOS3 (0.41) | — | |
| SCHEMBL1924446 | 0.69 | — | — | |
| SCHEMBL4140258 | 0.69 | CCR1 (0.41) | CCR1PIK3CAPI4KAPI4KBALDH1A1 | |
| SCHEMBL1962963 | 0.69 | ADRA2A (0.38) | — | |
| SCHEMBL12162594 | 0.68 | PIK3CA (0.41) | CCR1PIK3CAPI4KAPI4KBS1PR1 | |
| SCHEMBL2380517 | 0.68 | HRH3 (0.50) | CCR1PIK3CAPI4KAPI4KBS1PR1 | |
| SCHEMBL2098949 | 0.68 | KMT2A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242974-B2 | Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140073797-A1 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8552162-B2 | Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2009137787-A1 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281293-A1 | PROCESSES FOR THE PREPARATION OF 2 FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073797-A1 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | CYP2F1, CYP2B6, CYP4F11 | CCR1 997/4885PIK3CA 3013/4885PI4KA 3770/4885 |
| US-20090281293-A1 | PROCESSES FOR THE PREPARATION OF 2 FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | CYP2F1, CYP2B6, CYP4F11 | CCR1 941/4885PIK3CA 2823/4885PI4KA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.